Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (TCTR20251010003) titled 'A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Fixed-dose Combination of Empagliflozin and Linagliptin 10/5 mg FCT (Empagliflozin and Linagliptin Tablets 10/5mg) and Reference Product (Glyxambi 10/5 mg FCT) in Healthy Thai Volunteers under Fasting Conditions' on Oct. 10.
Study Type: Interventional
Study Design:
Randomized
Primary Sponsor: International Bio Service Co., Ltd.
Condition:
Bioequivalence study in healthy Thai volunteers
Empagliflozin and Linagliptin Bioequivalence study, Healthy
Empagliflozin and Linagliptin Bioequivalence study, Healthy
Intervention:
E...